November 10, 2017 06:45 AM EST
Bioregnum
Opinion

With re­lo­ca­tion vote loom­ing, the EMA is open­ly fret­ting as cities jock­ey for at­ten­tion

The biggest de­ci­sion that the EMA faces has noth­ing to do with any drug an­gling for a Eu­ro­pean ap­proval or how it’s do­ing rel­a­tive to …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times